Last updated 16 days ago
Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
84 patients around the world
Available in Chile, United States
The study duration per participant will be up to 116 weeks.
Sanofi
1Research sites
84Patients around the world
This study is for people with
Hidradenitis suppurativa
Requirements for the patient
To 70 Years
All Gender
Medical requirements
SponsorSanofi
Conditions
Requirements
To 70 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06118099
